CO2020015476A2 - Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje - Google Patents
Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltajeInfo
- Publication number
- CO2020015476A2 CO2020015476A2 CONC2020/0015476A CO2020015476A CO2020015476A2 CO 2020015476 A2 CO2020015476 A2 CO 2020015476A2 CO 2020015476 A CO2020015476 A CO 2020015476A CO 2020015476 A2 CO2020015476 A2 CO 2020015476A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- voltage
- potassium channel
- gated potassium
- bioavailability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En determinadas modalidades, la presente descripción se dirige a métodos y usos para tratar trastornos convulsivos en un ser humano, en los que los métodos y usos comprenden la administración oral de una cantidad terapéuticamente efectiva del modulador alostérico del canal de potasio dependiente de voltaje, N- [4- (6-fluoro-3,4-dihidro-1H-isoquinolin-2-il) -2,6-dimetilfenil] -3,3-dimetilbutanamida (Compuesto A), al ser humano que lo necesite, por ejemplo, en condiciones de alimentación. La presente descripción se dirige además a varios métodos mejorados de terapia y administración del Compuesto A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| PCT/US2019/031872 WO2019217924A1 (en) | 2018-05-11 | 2019-05-10 | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020015476A2 true CO2020015476A2 (es) | 2021-01-29 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0015476A CO2020015476A2 (es) | 2018-05-11 | 2020-12-11 | Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US11135214B2 (es) |
| EP (2) | EP3790548B1 (es) |
| JP (1) | JP2021523130A (es) |
| KR (1) | KR20210020892A (es) |
| CN (1) | CN112384216A (es) |
| AU (1) | AU2019265002A1 (es) |
| BR (1) | BR112020022713A2 (es) |
| CA (1) | CA3099292A1 (es) |
| CL (1) | CL2020002932A1 (es) |
| CO (1) | CO2020015476A2 (es) |
| CR (1) | CR20200602A (es) |
| DK (1) | DK3790548T3 (es) |
| EA (1) | EA202092720A1 (es) |
| ES (1) | ES2964409T3 (es) |
| FI (1) | FI3790548T3 (es) |
| GE (1) | GEP20237527B (es) |
| HR (1) | HRP20231447T1 (es) |
| HU (1) | HUE064326T2 (es) |
| LT (1) | LT3790548T (es) |
| MA (1) | MA52569B1 (es) |
| MD (1) | MD3790548T2 (es) |
| MX (1) | MX2020012008A (es) |
| PE (1) | PE20211211A1 (es) |
| PH (1) | PH12020551898A1 (es) |
| PL (1) | PL3790548T3 (es) |
| PT (1) | PT3790548T (es) |
| RS (1) | RS64922B1 (es) |
| SG (1) | SG11202011102TA (es) |
| SI (1) | SI3790548T1 (es) |
| UA (1) | UA127229C2 (es) |
| WO (1) | WO2019217924A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3790548T2 (ro) | 2018-05-11 | 2024-02-29 | Xenon Pharmaceuticals Inc | Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| TW202133847A (zh) * | 2019-12-06 | 2021-09-16 | 加拿大商再諾製藥公司 | 治療疼痛的方法 |
| KR20240004238A (ko) * | 2021-02-09 | 2024-01-11 | 제논 파마슈티칼스 인크. | 발작 장애를 치료하기 위한 합동 요법 |
| CN116847843A (zh) | 2021-02-09 | 2023-10-03 | 泽农医药公司 | 用于治疗快感缺乏的电压门控的钾通道开放剂 |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
| KR20230060487A (ko) * | 2021-10-27 | 2023-05-04 | 상하이 지멍 바이오파마 아이엔씨 | 칼륨 채널 조절제로 사용되는 화합물 및 이의 제조 및 응용 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| PL1891089T3 (pl) | 2005-06-02 | 2015-05-29 | Merck Sharp & Dohme | Inhibitory proteazy HCV w połączeniu z pokarmem |
| JP2009535370A (ja) | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| NZ575652A (en) | 2006-08-23 | 2011-08-26 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| MD3790548T2 (ro) | 2018-05-11 | 2024-02-29 | Xenon Pharmaceuticals Inc | Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente |
-
2019
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 AU AU2019265002A patent/AU2019265002A1/en active Pending
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/en active Active
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/en active Application Filing
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-10 CA CA3099292A patent/CA3099292A1/en active Pending
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko unknown
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/en active Pending
- 2019-05-10 JP JP2020562201A patent/JP2021523130A/ja active Pending
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020015476A2 (es) | Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje | |
| BR112022010924A2 (pt) | Tetra-hidrofuranos substituídos como moduladores de canais de sódio | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| MX2022008479A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CL2019002031A1 (es) | Moduladores del canal de potasio. | |
| CL2023002321A1 (es) | Abridor de canales de potasio activado por voltaje para uso en el tratamiento de la anhedonia. | |
| CL2022001477A1 (es) | Uso de un abridor de canal de potasio kv7 para tratar el dolor | |
| MX2021006242A (es) | Formulaciones de capsula. | |
| EA202191063A1 (ru) | Новая дозированная форма | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
| EA202092051A1 (ru) | Спироциклические модуляторы ror-гамма | |
| RU2018111990A (ru) | Лекарственные экстракты растений амброзии | |
| CL2022000639A1 (es) | Métodos de uso para activadores de canal kv7 | |
| EA202092449A1 (ru) | ИНГИБИТОРЫ Bcl-2 | |
| CL2023002323A1 (es) | Terapia conjunta para el tratamiento de trastornos convulsivos | |
| CO2021013311A2 (es) | Inhibidores del canal de potasio novedosos | |
| EA201792133A1 (ru) | Фармацевтическая композиция для местного применения с анальгетическим и противовоспалительным действием | |
| BR112022007826A2 (pt) | Combinações de 1-(((2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il)metóxi)-7-metóxi-isoquino¬lina-6-carboxamida e formas de dosagem oral | |
| PL425356A1 (pl) | Zastosowanie α,β dihydroksantohumolu | |
| EA201992338A1 (ru) | Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний | |
| EA201992690A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря |